» Articles » PMID: 26073375

Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma

Overview
Specialty Gastroenterology
Date 2015 Jun 16
PMID 26073375
Citations 246
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric cancer (GC) is globally the fifth most common cancer and third leading cause of cancer death. A complex disease arising from the interaction of environmental and host-associated factors, key contributors to GC's high mortality include its silent nature, late clinical presentation, and underlying biological and genetic heterogeneity. Achieving a detailed molecular understanding of the various genomic aberrations associated with GC will be critical to improving patient outcomes. The recent years has seen considerable progress in deciphering the genomic landscape of GC, identifying new molecular components such as ARID1A and RHOA, cellular pathways, and tissue populations associated with gastric malignancy and progression. The Cancer Genome Atlas (TCGA) project is a landmark in the molecular characterization of GC. Key challenges for the future will involve the translation of these molecular findings to clinical utility, by enabling novel strategies for early GC detection, and precision therapies for individual GC patients.

Citing Articles

Helicobacter pylori, microbiota and gastric cancer - principles of microorganism-driven carcinogenesis.

Wizenty J, Sigal M Nat Rev Gastroenterol Hepatol. 2025; .

PMID: 40011753 DOI: 10.1038/s41575-025-01042-2.


The Role of Yes-Associated Protein in Autophagy and Tumor Progression in Gastric Cancer.

Jin Y, Cheng H, Hu X, Cao J Mol Biotechnol. 2025; .

PMID: 39976859 DOI: 10.1007/s12033-024-01354-9.


Single-cell profiling reveals a reduced epithelial defense system, decreased immune responses and the immune regulatory roles of different fibroblast subpopulations in chronic atrophic gastritis.

Lin L, Huang T, Li L, Lin Y, Chen F, Zheng Z J Transl Med. 2025; 23(1):159.

PMID: 39905493 PMC: 11796052. DOI: 10.1186/s12967-025-06150-w.


Deciphering the Differences Between Epstein-Barr Virus-Associated and Negative Gastric Cancer in the Prospect of CDKN2A Genomic Alterations and Lymphoid Infiltration.

Xie F, Chen B, Lyu Y, Yu P, Fang C, Leung K Cancer Med. 2025; 14(2):e70409.

PMID: 39844467 PMC: 11754542. DOI: 10.1002/cam4.70409.


eradication for primary prevention of gastric cancer: progresses and challenges.

Liu Z, Xu H, You W, Pan K, Li W J Natl Cancer Cent. 2024; 4(4):299-310.

PMID: 39735441 PMC: 11674435. DOI: 10.1016/j.jncc.2024.06.006.